Allergan has completed its acquisition of Kythera Biopharmaceuticals in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds KYBELLA (deoxycholic acid), the first FDA approved non-surgical injection for improvement in the appearance of moderate to severe submental fullness, to Allergan’s portfolio. In addition, Allergan also gains Kythera's development product setipiprant (KYTH-105), a novel compound for the prevention of androgenetic alopecia (AGA), or male pattern hair loss. Kythera has already submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for setipiprant for the treatment of AGA. Allergan plans to conduct a human proof-of-concept study to evaluate the efficacy and safety of setipiprant in male subjects with AGA.
“The completion of the Kythera acquisition is an important moment for Allergan and our world-class aesthetics business, adding highly differentiated products and development programs that enhance our product offering to global customers and their patients,” said Brent Saunders, CEO and president of Allergan.